Meta-analysis and GRADE Evaluation of Modified Wumei Pill in the Treatment of Parkinson's Disease
Objective:To systematically evaluate the efficacy and safety of modified Wumei Pill in the treatment of parkinson's disease(PD).Methods:The randomized controlled trials(RCT)on the treatment of PD with Wumei Pill were searched in Cochrane Library,EMBASE,Web of Science,PubMed,CNKI and CBM databases and clinical trial centers,with the search time from database establishment to April 2023.After data collection and data extraction,8 studies were finally included.226 cases were included in the treatment group(Wumei Pill)and the control group,respectively.Meta-analyses were performed using RevMan 5.3 and stata14 software,and GRADEpro GDT was used to evaluate the quality of evidence for each outcome measure.Results:The scores of all scales of the unified Parkinson's disease rating scale(UPDRS)in the treatment group were significantly lower than those in the control group,and the improvements in UPDRS Ⅰ,Ⅲ and Ⅳ were statistically significant,with the results being[MD=-0.769,respectively.95％CI(-1.213～-0.324),P=0.001],[MD=-2.211,95％CI(-2.713～-1.708),P=0],[MD=-0.526,95％CI(-1.041～0.012),P=0.045].There was no significant difference in UPDRS score between the two groups[MD=3.964,95％CI(-9.465～17.392),P=0.563].The treatment group could significantly improve the treatment effective rate,and the difference was statistically significant[RR=1.709,95％CI(1.361-2.145),P=0].No adverse events or treatment-related abnormalities were found in any of the studies.GRADE evidence quality grading results were moderate in UPDRS Ⅰ,UPDRS Ⅲ,UPDRS Ⅳ and effec-tive rate,low in UPDRS Ⅱ,and very low in UPDRS total score.Conclusion:The modified Wumei Pill has a certain effect on the treatment of PD,and has good safety.
万方数据
维普
